MARKET

AEZS

AEZS

Aeterna Zentaris
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9047
-0.0054
-0.59%
Opening 12:14 06/24 EDT
OPEN
0.9100
PREV CLOSE
0.9101
HIGH
0.9419
LOW
0.8982
VOLUME
722.78K
TURNOVER
--
52 WEEK HIGH
3.620
52 WEEK LOW
0.2900
MARKET CAP
109.61M
P/E (TTM)
-4.4588
1D
5D
1M
3M
1Y
5Y
Hedge Funds Are Buying AEterna Zentaris Inc. (AEZS)
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in re...
Insider Monkey · 06/13 18:10
Mid-Day Market Update: United Natural Foods Falls On Sales Miss; Aethlon Medical Shares Jump
Midway through trading Wednesday, the Dow traded up 0.09% to 34,631.35 while the NASDAQ rose 0.29% to 13,964.96. The S&P also rose, gaining 0.15% to 4,233.76.
Benzinga · 06/09 16:24
Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
– Dr. Levy is a well-established neuroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders – Company continues to advance development of its AIM Biologicals pre-clinical program, seeking to devel...
GlobeNewswire · 06/07 12:05
Aeterna Zentaris Starts Animal Studies For Macimorelin For Amyotrophic Lateral Sclerosis
Benzinga · 05/17 14:12
Aeterna Zentaris starts preclinical development of macimorelin in amyotrophic lateral sclerosis
Aeterna Zentaris (AEZS) has commenced the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), the
Seekingalpha · 05/17 13:00
BRIEF-Aeterna Zentaris - Preclinical Program To Qualify Macimorelin For Clinical Development As Potential Treatment Option For Amyotrophic Lateral Sclerosis
reuters.com · 05/17 12:21
Aeterna Zentaris Announces Start Of Preclinical Development Of Macimorelin At The University Of Queensland As A Potential New Treatment Option For Patients With Amyotrophic Lateral Sclerosis
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (the "Company" or "Aeterna Zentaris"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of
Benzinga · 05/17 12:11
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's Disease)
- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of macimorelin for the treatment of ALS
GlobeNewswire · 05/17 12:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AEZS. Analyze the recent business situations of Aeterna Zentaris through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AEZS stock price target is 4.500 with a high estimate of 4.500 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 47
Institutional Holdings: 2.25M
% Owned: 1.86%
Shares Outstanding: 121.15M
TypeInstitutionsShares
Increased
8
110.31K
New
16
1.65M
Decreased
4
551.89K
Sold Out
5
229.11K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.64%
Pharmaceuticals & Medical Research
+1.11%
Key Executives
Chairman/Independent Director
Carolyn Egbert
President/Chief Executive Officer/Director
Klaus Paulini
Chief Financial Officer/Senior Vice President
Leslie Auld
Vice President - Finance
Guenther Grau
Vice President
Nicola Ammer
Vice President
Matthias Gerlach
Vice President - Business Development
Eckhard Gunther
Director
Gilles Gagnon
Independent Director
Robin Hoke
Independent Director
Brent Norton
No Data
  • All
  • Financials
  • Insiders
More
About AEZS
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Webull offers kinds of AEterna Zentaris Inc. (USA) stock information, including NASDAQ:AEZS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEZS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AEZS stock methods without spending real money on the virtual paper trading platform.